Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). (Q43671434)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS) (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

6

Michael Good

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

8

Anton P J Middelberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Tania Rivera-Hernandez

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Jon Hartas

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yang Wu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Yap P Chuan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Michael R Batzloff

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

language of work or name

English

0 references

publication date

17 February 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

1950-1955

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

The current challenges for vaccine development

24 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Vaccine manufacturing: challenges and solutions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

The global burden of group A streptococcal diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Prevalence of rheumatic heart disease detected by echocardiographic screening.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Opsonic human antibodies from an endemic population specific for a conserved epitope on the M protein of group A streptococci

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Mapping the minimal murine T cell and B cell epitopes within a peptide vaccine candidate from the conserved region of the M protein of group A streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Protection against group A streptococcus by immunization with J8-diphtheria toxoid: contribution of J8- and diphtheria toxoid-specific antibodies to protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Moving forward: a mucosal vaccine against group A streptococcus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

7 January 2021

Nasal vaccine innovation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Hepatitis B vaccines: protective efficacy and therapeutic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

7 January 2021

HPV vaccine: Cervarix

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Virus-like particles as a vaccine delivery system: myths and facts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Towards the preparative and large-scale precision manufacture of virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

High-level expression of soluble viral structural protein in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Quantitative analysis of virus-like particle size and distribution by field-flow fractionation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

A microbial platform for rapid and low-cost virus-like particle and capsomere vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Microbial production of virus-like particle vaccine protein at gram-per-litre levels.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Virus assembly occurs following a pH- or Ca2+-triggered switch in the thermodynamic attraction between structural protein capsomeres.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Toward the development of an antidisease, transmission-blocking intranasal vaccine for group a streptococcus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Mucosal immunization: a realistic alternative

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Pathogenesis of group A streptococcal infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Passive acquired mucosal immunity to group A streptococci by secretory immunoglobulin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Functional analysis of IgA antibodies specific for a conserved epitope within the M protein of group A streptococci from Australian Aboriginal endemic communities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

Vaccine strategies to prevent rheumatic fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.02.013

10.1016/J.VACCINE.2013.02.013

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23422147%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference